RenovoRx, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RNXT research report →
Price Chart
About the company
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination.
- CEO
- Shaun R. Bagai
- IPO
- 2021
- Employees
- 17
- HQ
- Mountain View, CA, US
Get TickerSpark's AI analysis on RNXT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $45.45M
- P/E
- -3.32
- Fwd P/E
- 25.69
- PEG
- -0.26
- P/S
- 18.25
- P/B
- 5.45
- EV/EBITDA
- -3.12
- Div Yield
- 0.00%
- Gross Margin
- 84.04%
- Op Margin
- -483.93%
- Net Margin
- -469.02%
- ROE
- -149.01%
- ROIC
- -128.20%
Latest fiscal year · YoY change
- Revenue
- $1.12M+2511.6%
- Gross Profit
- $796.00K+1751.2%
- Op Income
- $-12,510,000
- Net Income
- $-11,168,000-26.7%
- EPS
- $-0.32+13.5%
- OCF Growth
- -20.3%
- FCF Growth
- -20.1%
- 52W High
- $2.59
- 52W Low
- $0.77
- 50D MA
- $1.35
- 200D MA
- $1.11
- Beta
- 0.97
- RSI (14)
- 36
- Avg Volume
- 815.75K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
RenovoRx posted its first quarterly revenue above $1 million, expanded active centers and pipeline, and reaffirmed full-year guidance while pointing to continued commercial and clinical momentum.· November 5, 2026
- Q3 revenue hit a record $1.07 million, up about 17% sequentially and more than 4x year over year.
- Active commercial cancer centers increased to 26 from 21 in Q2, with more than 40 additional centers in the funnel and a year-end target of 36 active centers.
- Gross margin was 82%; management said underlying gross margin was 85% after excluding a GAAP reclassification tied to trial-device conversions.
- The Phase III TIGeR-PaC trial completed enrollment; top-line data are expected in the second half of 2027.
- Management maintained full-year 2026 revenue guidance of $3.75 million to $4.25 million and said cash of $10.4 million funds operations into the second half of 2027.
RenovoRx reported Q3 2026 revenue of $1.07 million, up approximately 17% sequentially and more than 4x the $266,000 reported in Q3 2025. Gross profit was $878,000 and gross margin was 82%; management said underlying gross margin would have been 85% excluding a GAAP reclassification tied to three device conversions. R&D expense was approximately $1.2 million versus $1.7 million a year ago, SG&A was approximately $2.9 million versus $1.7 million, operating loss was approximately $3.2 million, net loss was $3.6 million or $0.08 per share, and cash and cash equivalents were approximately $10.4 million at quarter-end versus $9.5 million at June 30. Management reaffirmed full-year 2026 revenue guidance of $3.75 million to $4.25 million and said cash runway extends into the second half of 2027.
Shaun Bagai framed Q3 as a milestone quarter because RenovoRx crossed the $1 million quarterly revenue mark, added active centers, and expanded TAMP beyond locally advanced pancreatic cancer. He emphasized that new account activations are the key leading indicator for revenue and said the company’s focused U.S. sales force is sized to cover the concentrated pancreatic cancer center market. His tone was upbeat and confident, highlighting repeat ordering, a funnel of more than 65 centers in total, new publications, a sarcoma use case, and the first patient in a neoadjuvant IIT as evidence of broader adoption potential.
Mark Voll focused on the numbers and operating leverage: $1.07 million in revenue, $878,000 in gross profit, 82% gross margin, and an underlying 85% margin excluding a device reclassification. He attributed lower R&D to reduced Phase III TIGeR-PaC costs after enrollment completion, while SG&A rose to $2.9 million because of commercial infrastructure build-out. He also highlighted improved cash of $10.4 million, supported by $3.5 million of warrant exercises, and said the company believes it has runway into the second half of 2027 while working toward cash flow positive operations.
Analysts asked whether the approval of a new pancreatic cancer therapy could change chemotherapy use and how RenovoCath might be used with new agents; management said it should not initially displace chemotherapy, noted the therapy was studied in a second-line metastatic setting, and said RenovoCath could potentially be used with RAS inhibitors, oxaliplatin, or other agents over time. Another question focused on PRISM-TAMP and where TAMP fits relative to systemic chemo and surgery; management said it moves treatment earlier in the pathway for borderline resectable patients, typically after upfront systemic therapy and radiation, with the goal of reaching surgery faster. When asked about adding more sales staff, management said the company is already fully staffed with 5 U.S. field reps and believes that is sufficient given how concentrated the market is, though they would consider adding more if needed.
The call showed accelerating commercialization: revenue crossed $1 million for the first time, active centers rose to 26, and repeat ordering continued from existing customers. Management also pointed to a growing evidence base, completion of TIGeR-PaC enrollment, and early expansion into sarcoma and neoadjuvant use as signs the platform may have broader utility than originally targeted.
The company is still loss-making, with a $3.2 million operating loss and $3.6 million net loss in the quarter, and commercialization remains dependent on continued center activation and repeat use. Management also acknowledged that some margin figures were affected by accounting reclassification and that the clinical readout from TIGeR-PaC is still far away, with initial top-line data expected in the second half of 2027.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 96.3%
- Shares Outstanding
- 48.25M
- Float Shares
- 46.48M
of shares held by institutions
29 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Aigh Capital Management LLC | 4.26M | ▼ 141.82K |
| Vanguard Capital Management LLC | 1.67M | ▲ 224.62K |
| Bleichroeder LP | 1.67M | 0 |
| Vanguard Group Inc | 1.61M | 0 |
| Renaissance Technologies LLC | 1.12M | ▲ 1.11M |
| Geode Capital Management, LLC | 473.09K | ▲ 48.95K |
| State Street Corp | 314.64K | ▲ 288.48K |
| Informed Momentum Co LLC | 272.71K | ▲ 272.71K |
| Vanguard Fiduciary Trust Co | 269.92K | ▲ 29.59K |
| Walleye Capital LLC | 262.11K | ▲ 262.11K |
| Wealthspire Advisors, LLC | 252.53K | 0 |
| Bank Of America Corp | 194.43K | ▲ 194.43K |
Held by 23 ETFs
Biggest fund positions in RNXT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | Stark Richard | other | 128,824 |
| Nov 18, 26 | Stark Richard | other | 0 |
| Nov 18, 26 | Stark Richard | other | 0 |
| Nov 18, 26 | Stark Richard | other | 0 |
| Nov 16, 26 | Agah Ramtin | buy | 50,000 |
| Oct 1, 26 | Macfarlane K. Angela | other | 55,924 |
| Oct 1, 26 | Spiegel Robert J. | other | 55,924 |
| Oct 1, 26 | RYAN UNA S | other | 55,924 |
| Oct 1, 26 | Marton Laurence | other | 55,924 |
| Sep 10, 26 | VOLL MARK | other | 80,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RNXT coverage
Recent articles, reports, and earnings notes.
No research on RNXT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RNXT report →RenovoRx Appoints Interventional Oncology Medtech Leader Richard Stark to its Board of Directors
globenewswire.com · Nov 19
RenovoRx Q3 Earnings Call Highlights
marketbeat.com · Nov 6
RenovoRx, Inc. (RNXT) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
RenovoRx, Inc. (RNXT) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Nov 5
RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million
globenewswire.com · Nov 5
RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum
globenewswire.com · Oct 28
RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
globenewswire.com · Oct 22
RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
globenewswire.com · Oct 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.